Jones Day represented and supported Sanofi's in-house team in its strategic collaboration with Janssen Pharmaceuticals, now “Johnson & Johnson Innovative Medicine," in connection with a Co-Development, Co-Commercialization & License Agreement with Johnson & Johnson's Janssen Pharmaceuticals relating to ...
In the Phase I dose escalation portion, argenx evaluated 12 newly diagnosed AML patients unfit for intensive chemotherapy. Patients received cusatuzumab in combination with Vidaza. The new data showed an overall response rate (ORR) across the 12 patients of 92% (11/12 patients), inc...
A BLAST (Basic Local Alignment Search Tool; Altschul et al., 1990 J. Mol. Biol. 215, 403–410) search was performed in the proprietary LifeSeq™ human EST database (Incyte Pharmaceuticals, Inc., Palo Alto, Calif., USA). BLAST produces alignments of both nucleotide and amino acid sequen...